RARE: Ultragenyx Pharmaceutical Inc. Company Total Revenue

ultragenyx.com - graphic logo of issuer RARE

Ultragenyx Pharmaceutical is optimizing its processes by outsourcing clinical trials and drug manufacturing to third-party contractors. High R&D investments and patents create significant barriers to entry for competitors under strict FDA oversight. Innovative treatments for rare pathologies are demonstrating steady growth. The company's product revenue on this chart shows that the current level is around 0.73.

Ultragenyx Corp - RARE Company Sales (period 07/04/2022 - 11/18/2026)

Comprehensive metric breakdowns and analytics for Ultragenyx Pharma (RARE)

- current price and projected stock value:
Summary company analysis:RARE, ultragenyx.com
Manufactured products of Ultragenyx Pharmaceutical Inc.

Investors should utilize this indicator to filter out overvalued assets and verify the actual market value of Ultragenyx Pharmaceutical (RARE). Given the outsourcing of production to CMOs to minimize capital expenditures, the company's commercial revenue trend reflects the effectiveness of orphan drug commercialization, where turnover growth confirms an operational peak, while stagnation signals critical risks to business sustainability.

Analysis of competing companies

Tempus AI, Inc. (TEM) - Company Gross Revenue|Company Sales QGEN (Qiagen NV)|Revenue and Sales Volume Ionis Pharmaceuticals, Inc. (IONS)|Revenue and Sales Volume RGEN (Repligen Inc.)|Avidity Corp (RNA) - Company Total Revenue|CRSP - Company Revenue|Company Gross Revenue genedx.com WGS|BEAM: Revenue and Sales Volume|Sarepta - Company Sales Revenue|TWST (twistbioscience.com) - Revenue and Sales Volume|Company Sales Volume TXG (10x Genomics Corp)|Revenue and Sales Volume NTLA|Revenue and Sales Volume Stoke Therapeutics, Inc. (STOK)|Company Revenue BioLife BLFS|WVE - Company Sales|Maze Therapeutics Corp - Revenue and Sales Volume|Sionna Pharma - Company Total Sales|Prime Medicine (PRME) - Company Revenue|tayshagtx.com (TSHA) - Revenue and Sales Volume|Company Revenue uniQure Corp|MGTX: Company Sales Revenue|Revenue and Sales Volume RGNX|Company Gross Revenue Solid Corp|Revenue and Sales Volume OCGN (ocugen.com)|PACB (Pacific Biosciences) - Company Annual Revenue|Benitec Biopharma Inc - Revenue and Sales Volume|Company Gross Revenue Design Therapeutics, Inc. DSGN|Rocket Corp (RCKT) - Company Revenue|4D Molecular Therapeutics (FDMT) - Revenue and Sales Volume|LXEO (Lexeo Therapeutics, Inc.) - Revenue and Sales Volume|Company Total Revenue korrobio.com KRRO|Company Sales EDIT (Editas Medicine, Inc.)|Silence Therapeutics plc - Company Sales Volume|Company Revenue ProQR Therapeutics N.V. PRQR|Company Gross Revenue Codexis, Inc. (CDXS)|SGMO - Company Revenue|nautilus.bio - Company Total Sales|Metagenomi, Inc (MGX) - Company Revenue|Company Sales Volume DTIL|Company Revenue Generation Bio|Revenue and Sales Volume Boundless Bio Inc|Company Revenue Exicure Corp (XCUR)|Company Gross Revenue Imunon|Revenue and Sales Volume PHIO (phiopharma.com)|Company Total Sales Volume mustangbio.com|RNAZ - Company Revenue|Company Total Revenue Bionano Genomics|APDN: Revenue and Sales Volume|Company Sales Volume BLUE|Company Sales IPA|OMGA: Company Sales Revenue|Revenue and Sales Volume OMIC|Company Gross Revenue Regulus Therapeutics|Company Revenue Syros SYRS|Company Sales Revenue TBIO|TCON: Company Sales|Unity Biotechnology, Inc. (UBX) - Company Sales